Home » The Lancet Publishes Results from Gentium’s Phase III Defibrotide Trial for the Prevention of VOD in Pediatric Patients
The Lancet Publishes Results from Gentium’s Phase III Defibrotide Trial for the Prevention of VOD in Pediatric Patients
Gentium announced that results from a Phase III randomized controlled trial which evaluated Defibrotide for use in preventing hepatic veno-occlusive disease (VOD) in paediatric patients undergoing haemopoietic stem-cell transplantation were published in the medical journal, The Lancet.
MarketWatch
MarketWatch
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May